MDM2 and cancer: Still, in p53 targeting, a disulfide-rich backbone-cyclised polypeptide showed efficient inhibition of interactions between p53 and its inhibitors MDM2 and MDMX, reducing cancer cell proliferation in vitro and reducing the tumour growth rate in mice [148].